Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Argus Health
McKinsey
Express Scripts
Johnson and Johnson

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,601,746

« Back to Dashboard

Which drugs does patent 7,601,746 protect, and when does it expire?

Patent 7,601,746 protects MULPLETA and is included in one NDA.

This patent has fifteen patent family members in nine countries.

Summary for Patent: 7,601,746
Title:Compounds exhibiting thrombopoietin receptor agonism
Abstract: A compound represented by the general formula (I): ##STR00001## wherein R.sup.1 is a hydrogen atom, a halogen atom, or the like; R.sup.2, R.sup.3, and R.sup.4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R.sup.5 is a hydrogen atom or the like; R.sup.6 and R.sup.7 are a hydrogen atom or the like; R.sup.8 is C1-C3 alkyl or the like; R.sup.9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.
Inventor(s): Takayama; Masami (Osaka, JP), Yoshida; Yutaka (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:10/567,993
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,601,746
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 7,601,746

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,601,746

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-292080Aug 12, 2003
PCT Information
PCT FiledAugust 10, 2004PCT Application Number:PCT/JP2004/011453
PCT Publication Date:February 17, 2005PCT Publication Number: WO2005/014561

International Family Members for US Patent 7,601,746

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004263442 ➤ Sign Up
Canada 2535511 ➤ Sign Up
China 102796058 ➤ Sign Up
China 103130739 ➤ Sign Up
China 1863783 ➤ Sign Up
European Patent Office 1655291 ➤ Sign Up
Spain 2599529 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Boehringer Ingelheim
McKinsey
US Department of Justice
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.